Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment.
That’s according to new data from the ULTIMATE Phase 3 trials, which continue to show that early treatment with high-efficacy therapies is associated with improved disability outcomes.
The findings were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, in Colorado and online…..Click HERE to read the full story.